The South African Health Products Regulatory Authority (SAHPRA) has become the fifth country in Africa, along with Nigeria, Tanzania, Ghana and Egypt, to become an ‘LM III’ (the third of four levels of the WHO classification) for vaccines.
Matshidiso Moeti, WHO Regional Director for Africa, revealed in a statement, noting that the designation, achieved after extensive reviews by international experts and following new protocols suggested by previous assessments, means the South Africa has been awarded a WHO rating “for ensuring the safety, quality and efficacy” of the vaccines it produces.
“We cannot talk about better health care without quality medical supplies. This is another important step not only for South Africa but for the region towards self-sufficiency in vaccines and medicines,” Ms. Moeti explained. “This achievement confirms South Africa’s pioneering effort in health research. Beyond its technical aspects, this milestone has real implications for people’s health. We cannot talk about better health care without quality medical supplies.
Additionally, WHO Director-General Tedros Ghebreyesus said, “This rapid progress in vaccine regulation is an important milestone for South Africa, the Southern Africa region and the continent.”
He added, “This is an important victory for vaccine equity, as the country is a major manufacturer of medical products, and this regulatory step will help maximize the impact of the vaccine technology center. to mRNA.
This achievement, he said, is testament to the role the regulator has played in ensuring that safe, effective and high-quality vaccines are available in South Africa.